The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,952,878 in first-year total cost, median $624,194.
Most frequent study sections
- Special Emphasis Panel[ZTR1 DPI-2 (01)]3
Most frequent institutions
- DUKE UNIVERSITY1
- NATIONAL JEWISH HEALTH1
- UNIVERSITY OF ALABAMA AT BIRMINGHAM1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis1UG3TR002445-01 | DOWNEY, GREGORY PAULDUDLEY, JOEL THOMASKAMINSKI, NAFTALI | NATIONAL JEWISH HEALTH, CO | $853,963 | ZTR1 |
| 2018 | AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease1UG3TR002450-01 | CUTTER, GARY RDRANSFIELD, MARK T | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $624,194 | ZTR1 |
| 2018 | AZD9668 and Neutrophil Elastase Inhibition to Prevent Graft-versus-Host Disease1UG3TR002448-01 | CHAO, NELSON J.PAVLETIC, STEVEN | DUKE UNIVERSITY, NC | $474,721 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.